Study of BW-50218 in Healthy Participants
ConditionHealthy Participants Study
Trial statusRecruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18-65
SponsorShanghai Argo Biopharmaceutical Co., Ltd.
About this trial
Phase 1, Single Ascending Dose Study of Subcutaneous BW-50218 in Healthy Participants
Eligibility criteria
Qualifiers
Capable of providing written informed consent and complying with all study procedures for the duration of the study.
Body weight and body mass index (BMI) within a range considered appropriate for study participation by the investigator.
Female participants must be non-pregnant, non-lactating, and either of non-childbearing potential or using highly effective contraception.
Male participants with partners of childbearing potential must agree to use effective contraception.
Disqualifiers
Any medical condition, recent illness, or laboratory result that, in the investigator's opinion, may increase risk or interfere with participation in the study.
Recent hospitalization or a significant acute medical event.
History of cancer or any long-term medical condition that the study doctor considers clinically relevant.
Clinical laboratory findings outside of range which are deemed clinically significant by the investigator at screening or Day -1.
Trial design
Treatments tested in this trial
- BW-50218 Injection
- Saline (0.9% NaCl)
Treatment groups
60 Participants
are divided into 7 treatment groups7
Treatment groupsSee each treatment group below.
Sponsors and collaborators
Source ClinicalTrials.gov